ALK Positive

ALK Positive Improving the life expectancy and quality of life for ALK-positive cancer patients worldwide.

🎬 The replay from our latest ALKtALK is now live on YouTube!We were joined by Alexander Spira, MD, PhD, FASCO, medical o...
04/25/2026

🎬 The replay from our latest ALKtALK is now live on YouTube!

We were joined by Alexander Spira, MD, PhD, FASCO, medical oncologist at Virginia Cancer Specialists and member of the ALK Positive Scientific Advisory Board, for a conversation about two clinical trials that could shape the future of ALK+ care: TRI-611 and Gilteritinib.

Dr. Spira shared what these trials are, what they could mean for our community, and answered questions directly from patients and care partners during a live Q&A.

Whether you joined us live or are watching for the first time, this is a conversation worth having. Staying informed and connected is one of the most powerful things we can do together.

▶️ Watch the replay here: https://www.youtube.com/watch?v=0DFJiwB9ZlM

ALKtALKs bring our community together with leading experts so we can all stay informed, ask better questions, and face ALK-positive cancer with the knowledge and support of one another. đź’™

After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff St...
04/22/2026

After discontinuing the NVL-655 trial due to liver toxicity, ALK-positive patient and ALK Positive board member, Jeff Sturm, accessed the investigational drug zidesamtinib through a single-patient IND. His experience highlights how physicians, researchers, and companies can sometimes work together to explore additional treatment options for patients.

Read Jeff’s full perspective and learn more about the SPIND process on our blog:
https://alkpositive.org/blog/patient-perspective-alternative-nuvalent-drug-for-patients-disqualified-from-nvl-655-due-to-liver-toxicity/

Learn About ALK+: Guardant360 Liquid BiopsyFor people living with ALK-positive cancer, understanding your tumor’s geneti...
04/19/2026

Learn About ALK+: Guardant360 Liquid Biopsy

For people living with ALK-positive cancer, understanding your tumor’s genetics can help guide treatment decisions. Guardant360 Liquid is an advanced blood-based liquid biopsy that can detect very small amounts of tumor DNA circulating in the bloodstream.

This highly sensitive test can help doctors identify important genetic changes—even when tissue biopsies are difficult to obtain—giving patients and care teams more information to guide care.

Learn how this test works and why it can be an important tool for ALK-positive patients and care partners:
https://alkpositive.org/blog/understanding-guardant360-liquid-biopsy/

🎥 REPLAY NOW AVAILABLE | ALKtALK with Dr. Jonathan Riess & Johanna HanIf you missed our live session, or want to watch i...
04/19/2026

🎥 REPLAY NOW AVAILABLE | ALKtALK with Dr. Jonathan Riess & Johanna Han

If you missed our live session, or want to watch it again, the replay is ready for you. 👇
▶️ https://youtu.be/ZExawDp9tAE?si=91u9VZ8yXyU_ooYf

Dr. Jonathan Riess, Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center, and Johanna Han, Assistant Director of the Early Phase Clinical Trials Program, sat down with us to break down single-patient INDs, who qualifies, realistic timelines, and what emerging therapies like ivonescimab could mean for ALK+ patients.

This one is packed with practical information for patients, care partners, and advocates.

Watch. Save. Share with someone who needs it. đź’™

🔬 ALK Positive is at the AACR Annual Meeting 2026 in San Diego, CA!The AACR Annual Meeting is the world's leading cancer...
04/18/2026

🔬 ALK Positive is at the AACR Annual Meeting 2026 in San Diego, CA!

The AACR Annual Meeting is the world's leading cancer research conference — where the brightest minds in oncology come together to share breakthrough science, advance clinical research, and shape the future of cancer care.

Our Executive & Medical Director, Dr. Ken Culver, and Medical Team Project Manager, Sadia Yaakov, are on the ground this week, soaking up the latest in ALK-positive research and advocating for our community where it matters most — at the forefront of the science.

If you're at , come find them and say hello. They'd love to connect! đź‘‹

Research Update: TKI + ChemotherapyA recent multi-center study explored outcomes for ALK-positive NSCLC patients who con...
04/18/2026

Research Update: TKI + Chemotherapy

A recent multi-center study explored outcomes for ALK-positive NSCLC patients who continued their ALK TKI alongside platinum/pemetrexed chemotherapy after disease progression.

The findings suggest that maintaining targeted therapy during chemotherapy may improve overall survival and reduce the risk of brain progression in certain patients—supporting a strategy many ALK experts have long used in clinical practice.

Learn more about the research findings: https://alkpositive.org/blog/continuing-alk-nsclc-tki-treatment-while-on-chemotherapy-leads-to-better-outcomes/

At the Genentech Experience Exchange for Patient Advocates this week in San Francisco, Ken Culver, our Executive and Med...
04/17/2026

At the Genentech Experience Exchange for Patient Advocates this week in San Francisco, Ken Culver, our Executive and Medical Director, joined more than 120 organizations coming together to support the cancer community.

The meeting included sessions on Genentech’s oncology pipeline, along with breakout discussions on access, clinical trial enrollment, and new tools in development to better support patients.

We are proud to represent the ALK-positive cancer community and to collaborate alongside partners dedicated to improving care, expanding access, and driving better outcomes.

04/12/2026

New Healing Arts Group: Non-Metastatic ALKies 🎨

Navigating Stage 1–3c ALK-positive cancer comes with its own unique set of hurdles. Whether you’re currently in the thick of curative treatment or managing the "what comes next" of life after diagnosis, you don’t have to do it alone. 💙

We are thrilled to announce Non-Metastatic ALKies, a dedicated Healing Arts group designed specifically for our early-stage and locally advanced community.

Event Details
• Date: Monday, April 13
• Time: 7:00pm – 8:00pm ET
• Learn More & Join Here: https://alkpositive.org/event/non-metastatic-alkies/2026-04-13/

We’re proud to be attending the 2026 Texas Lung Cancer Conference, joining 100+ key opinion leaders and even more oncolo...
04/11/2026

We’re proud to be attending the 2026 Texas Lung Cancer Conference, joining 100+ key opinion leaders and even more oncologists dedicated to advancing lung cancer care.

Our Executive & Medical Director, Ken Culver, shared how energizing it’s been to see ALK fusions highlighted, including an ALK-positive patient-centered case discussion. He was especially inspired hearing Dr. Shirish Gadgeel say he “could talk about ALK+ all day,” which is a powerful reflection of the passion driving this work forward.

Showing up at meetings like this ensures the ALK-positive community stays top of mind in research, clinical trials, and drug development. We’re honored to be part of these important conversations.

The John Pender Scholarship Fund was created to honor the life and legacy of John Lynn Pender Jr.When John was diagnosed...
04/11/2026

The John Pender Scholarship Fund was created to honor the life and legacy of John Lynn Pender Jr.

When John was diagnosed with stage IV lung cancer at 37, he was given only 60 days to live. Instead, he lived 9 years, 9 months, and 10 days, always with a smile and a positive attitude.

Throughout his journey, John dedicated himself to helping others. He participated in research programs, donated blood and tissue to advance science, and raised awareness about lung cancer whenever he could.

Through the generosity of his wife Denise, this scholarship continues John’s legacy by supporting students connected to the ALK-positive community who are pursuing their education.

Learn more and apply:
https://alkpositive.org/blog/honoring-a-legacy-the-john-pender-scholarship-fund/

Applications close May 3.

Don’t miss this Sunday’s ALKtALK @ 7pm ET!Join us April 12 at 7pm ET for a live conversation with Dr. Alexander Spira, M...
04/10/2026

Don’t miss this Sunday’s ALKtALK @ 7pm ET!

Join us April 12 at 7pm ET for a live conversation with Dr. Alexander Spira, MD, PhD, FASCO, medical oncologist at Virginia Cancer Specialists and member of our Scientific Advisory Board.

This is an opportunity to hear directly from a leading expert about two clinical trials for ALK-positive patients, TRI-611 and Gilteritinib, and what they may mean for the community. Dr. Spira will also share insights on the latest research and treatment approaches.

Come with your questions and be part of the discussion during the live Q&A.

Can’t attend? The recording will be shared on our YouTube channel.

Address

6595 Roswell Road, Suite G2310
Atlanta, GA
30328

Website

https://secure.qgiv.com/for/am-ml/

Alerts

Be the first to know and let us send you an email when ALK Positive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ALK Positive:

Shortcuts

Share

Category